
Hayhurst Medical Technologies
Finding the curable cancer patients the system leaves behind.
Kansas City, Kansas, United States
Photos & Videos

Previous hero

Previous hero

Previous logo
Problem Statement
Every year, about 40,000 Americans qualify for a cancer surgery that could cure them, and roughly 90% are never found. The evidence is already in their records, sitting in radiology reports no one reads for candidacy. It is not a treatment gap; it is a detection and referral failure, and the patients missed most are in underserved, rural, and community settings.
Core Technology
Clinical AI that reads unstructured radiology and pathology reports at scale, extracting the findings that signal a curable patient and tracing each one back to its source sentence. An interpretable model scores surgical candidacy, maps it to the right specialist, and routes the patient, with a clinician approving every step, so there is no black box. Every case feeds a secure, outcome-linked cancer registry that improves the system with each patient.
Key Differentiators
The registry is the moat. Every case feeds a proprietary, outcome-linked dataset no incumbent holds and can’t easily assemble, so we get more accurate and more defensible with each patient. Interpretable, not a black box. Every finding traces back to its source sentence, and a clinician approves every step, which beats black-box AI on trust, adoption, and regulatory risk. We route; we don’t just flag. We assess surgical candidacy and send the patient to the right specialist. A clinician-plus-technical team. Two surgery-trained founders, one also an AI engineer, who live the problem, plus top CRS/HIPEC advisors and FDA-grade regulatory counsel. Live and deployed-ready today. Running on real de-identified clinical data, with EHR integration already in place at target hospitals.
Clinical Focus
Surgical oncology, beginning with peritoneal surface malignancy and candidacy for cytoreductive surgery with HIPEC, a potentially curative operation whose eligible patients are chronically under-identified and referred too late. The same detection-and-routing approach extends to other cancers where curable patients are missed. Decision support for the clinician making the referral, not autonomous diagnosis.
Target Customers
Hospitals and health systems, cancer centers, and the community, rural, and independent practices around them, the settings where curable patients are most often missed. We sell per-hospital software to the providers and programs that generate these patients, and partner with the surgical-oncology centers that receive the referrals. Research partners collaborate on the registry.
Product Stage
Beta
Company Info
- Business Model
- B2B SaaS. A recurring per-hospital software subscription for detection and navigation is the entry product and near-term revenue; a premium CT-imaging module follows as an upgrade once FDA-cleared; and the long-term asset is the proprietary, outcome-linked registry, licensable for research and real-world evidence. High software gross margins, low marginal cost per new hospital since EHR integration is already deployed. The software finds the patient; the data is the business.
- Founded
- 2026
- Total Funding
- Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now - Website
- hayhursttech.com
Categories
Clinical & IP
Clinical Validation
We validate candidacy against operative reports, the ground truth of what surgery actually found, and we deliberately test performance on incomplete, real-world community records. The system is live on real de-identified clinical data today. Our clinical advisors are the surgeons who perform this operation and confirm the miss is real. A leading clinical-AI accelerator gives us governed access to millions of de-identified records to validate at scale. Formal validation is ongoing; we are pre-deployment.
IP Protection
patents pending
Only accessible to MedStartr community members.
Join nowReviews
★★★★★5.0 · 1 review- AnonymousNov 16, 2026★★★★★5.0
- Clinical Benefit Potential 5/5
- Feasibility 5/5
- Innovativeness 5/5
- Fundability 5/5
- Scalability 5/5
- Presentation Quality 5/5
What do you think of Hayhurst Medical Technologies?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Comments
Comments from new members are shown once the company's team has approved them. Please follow the community rules.
Sign in to join the conversation.
Sign in to comment